Pierre Fabre and the European Organisation for Research and Treatment of Cancer (EORTC) have announced the screening of the first patient with a resected stage II BRAF-mutant melanoma for the Phase III study COLUMBUS-AD.
Log in met Medi-Access
Wilt u het gehele artikel lezen?
Log in met Medi-Access om verder te lezen
First patient enrolled in melanoma study
InPharm.com | Geplaatst op 24.05.2022 12:32